Free Trial
NYSEAMERICAN:LCTX

Lineage Cell Therapeutics (LCTX) Stock Price, News & Analysis

Lineage Cell Therapeutics logo
$0.41 -0.04 (-8.99%)
Closing price 04/1/2025 04:10 PM Eastern
Extended Trading
$0.42 +0.00 (+0.97%)
As of 08:07 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Lineage Cell Therapeutics Stock (NYSEAMERICAN:LCTX)

Key Stats

Today's Range
$0.40
$0.47
50-Day Range
$0.41
$0.72
52-Week Range
$0.40
$1.56
Volume
2.54 million shs
Average Volume
1.30 million shs
Market Capitalization
$90.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.20
Consensus Rating
Buy

Company Overview

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Remove Ads

Lineage Cell Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
34th Percentile Overall Score

LCTX MarketRank™: 

Lineage Cell Therapeutics scored higher than 34% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Lineage Cell Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Lineage Cell Therapeutics has only been the subject of 4 research reports in the past 90 days.

  • Read more about Lineage Cell Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Lineage Cell Therapeutics are expected to grow in the coming year, from ($0.12) to ($0.09) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Lineage Cell Therapeutics is -3.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Lineage Cell Therapeutics is -3.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Lineage Cell Therapeutics has a P/B Ratio of 1.17. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Lineage Cell Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    13.27% of the float of Lineage Cell Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Lineage Cell Therapeutics has a short interest ratio ("days to cover") of 12.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Lineage Cell Therapeutics has recently increased by 1.41%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Lineage Cell Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Lineage Cell Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    13.27% of the float of Lineage Cell Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Lineage Cell Therapeutics has a short interest ratio ("days to cover") of 12.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Lineage Cell Therapeutics has recently increased by 1.41%, indicating that investor sentiment is decreasing.
  • Search Interest

    Only 5 people have searched for LCTX on MarketBeat in the last 30 days. This is a decrease of -58% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Lineage Cell Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Lineage Cell Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    23.60% of the stock of Lineage Cell Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    62.47% of the stock of Lineage Cell Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Lineage Cell Therapeutics' insider trading history.
Receive LCTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lineage Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

LCTX Stock News Headlines

New “Trump” currency proposed in DC
According to one of the most connected men in Washington… A surprising new bill was just introduced in Washington. Its purpose: to put Donald Trump’s face on the $100 note. All to celebrate a new “golden age” for America.
See More Headlines

LCTX Stock Analysis - Frequently Asked Questions

Lineage Cell Therapeutics' stock was trading at $0.5150 on January 1st, 2025. Since then, LCTX stock has decreased by 20.2% and is now trading at $0.4110.
View the best growth stocks for 2025 here
.

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) announced its quarterly earnings data on Thursday, August, 8th. The company reported ($0.03) EPS for the quarter, topping analysts' consensus estimates of ($0.04) by $0.01. The company had revenue of $1.41 million for the quarter, compared to the consensus estimate of $1.28 million. Lineage Cell Therapeutics had a negative trailing twelve-month return on equity of 30.39% and a negative net margin of 230.66%.

Shares of LCTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Lineage Cell Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), Moderna (MRNA), JPMorgan Chase & Co. (JPM) and Chevron (CVX).

Company Calendar

Last Earnings
8/08/2024
Today
4/01/2025
Next Earnings (Estimated)
5/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSEAMERICAN:LCTX
Employees
60
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.20
High Stock Price Target
$9.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+921.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-21,490,000.00
Net Margins
-230.66%
Pretax Margin
-229.91%

Debt

Sales & Book Value

Annual Sales
$8.94 million
Price / Cash Flow
N/A
Book Value
$0.35 per share
Price / Book
1.17

Miscellaneous

Free Float
168,398,000
Market Cap
$90.59 million
Optionable
Not Optionable
Beta
1.21
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NYSEAMERICAN:LCTX) was last updated on 4/2/2025 by MarketBeat.com Staff
From Our Partners